Quick Take
Oyster Point Pharma (OYST) intends to raise $85 million in an IPO of its common stock, according to an S-1/A registration statement.
The company is advancing drug treatments for certain eye conditions.
OYST has a potential upside catalyst in mid-2020 and the IPO appears reasonably valued, so for life science investors with a hold timeframe of at least 12 to 18 months, the IPO may be worth considering.
Company & Technology
Princeton, New Jersey-based Oyster Point was founded in 2006 to develop new therapeutics for the treatment of eye diseases.